Georgia Institute of Technology

James Dahlman is a chemical and bioengineer whose work lies at the interface of nanotechnology, genomics, and gene editing. His research focuses on gene therapy, an experimental technique that uses genes to treat or prevent diseases, including hemophilia, Parkinson’s, cancer and HIV. Dahlman studied in vivo gene editing at the Broad Institute of Harvard and MIT; he received his Ph.D. from MIT and Harvard Medical School. Dahlman is interested in drug delivery, targeted in vivo gene editing and using genomics to improve biomaterial design.